Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice : Episode 13
Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.
EP: 1.Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
EP: 2.The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP: 3.Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials
EP: 4.Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC
EP: 5.Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial
EP: 6.The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP: 7.Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC
EP: 8.Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors
EP: 9.CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
EP: 10.KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC
EP: 11.EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC
EP: 12.POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC
Now Viewing
EP: 13.Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
EP: 14.The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC
EP: 15.The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC
EP: 16.A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations
EP: 17.The Exciting Future of NSCLC Treatment
EP: 18.Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
EP: 19.POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations
EP: 20.Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
EP: 21.Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations
EP: 22.Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations
Related Videos
Related Content
